COIOSDeep risk insights through multi-disciplinary research across the globe
Looking up at the tops of trees in a forest
Item confirms Peer-reviewed Added

SGLT2 inhibitors show no new safety signals in diabetic kidney disease

In two US claims cohorts with type 2 diabetes and stage III to IV kidney disease, SGLT2 inhibitors showed only the known genital infection signal against GLP-1 receptor agonists.

New users of SGLT2 inhibitors were compared with new users of GLP-1 receptor agonists in type 2 diabetes with stage III to IV kidney disease. A scan of all diagnosis codes in 22,328 Medicare and 8,918 commercial matched pairs detected genital infections in both sexes, and nothing else. No signal appeared in inpatient or emergency department codes.

Why it is interesting: An untargeted screen of every diagnosis code tests a class in patients often underrepresented in trials.

Source
American Journal of Kidney Diseases, 21 September 2026
Paper
Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD
Authors
Ortega-Montiel J, Alkabbani W, Hahn G, Liu J, Byrne CF, Wexler DJ et al.
DOI
10.1053/j.ajkd.2026.06.013
Type
Peer-reviewed article
Design
New-user active-comparator cohort with 1:1 propensity matching and tree-based scan statistic; 22,328 matched pairs (Medicare, 2016-2020) and 8,918 (MarketScan, 2016-2022)
Verdict
Confirms prior evidence
Free full text
Free to read at the publisher
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today